The Time Has Come

Labor Day Is Upon Us & Here’s Something Special For You From…

Algernon Announces Enrollment of 50th Patient in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

VANCOUVER, British Columbia, Sept. 02, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc.…

Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder

TORONTO, Sept. 02, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or…

4 Coronavirus Penny Stocks To Watch For September 2020

Are Coronavirus Penny Stocks On Your List This Month?

Revive Therapeutics Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

TORONTO, Aug. 31, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or…

New Wave Holdings Corp Appoints Dr. Wade Davis to Psychedelic Research Advisory Board

TORONTO, Aug. 31, 2020 /CNW/ – NEW WAVE HOLDINGS CORP. (the “Company”…

Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

Revive to also explore FDA Expanded Access Program (Compassionate Use) for Bucillamine in COVID-19

Revive Therapeutics to Expand Phase 3 Clinical Trial for Bucillamine in COVID-19 in Asia-Pacific and Canada

TORONTO, Aug. 19, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or…

Algernon CEO Presents Corporate Update Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

VANCOUVER, British Columbia, Aug. 17, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc.…

Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Aug. 14, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or…